<div id="readability-page-1"><div> By Katherine Hamilton <pre></pre> MiniMed shares rose after the company posted higher-than-expected revenue and expanded its partnership with Abbott Laboratories. The stock advanced 7% to $13.14 in pre-market trading Wednesday. The provider of diabetes management technology posted $837 million in sales in the fiscal fourth quarter, ahead of the $827.9 million analysts polled by FactSet expected. Revenue growth was driven by a 22% increase in international sales. MiniMed also said it expanded its agreement with Abbott to commercialize glucose-ketone sensors designed to integrate exclusively with MiniMed's smart dosing systems. The agreement builds on the companies' existing partnership for the Instinct sensor, made by Abbott. It will bring expanded choice to MiniMed users across automated insulin delivery and Smart MDI systems. <pre></pre> Write to Katherine Hamilton at katherine.hamilton@wsj.com <pre></pre> (END) Dow Jones Newswires June 03, 2026 09:49 ET (13:49 GMT)Copyright (c) 2026 Dow Jones &amp; Company, Inc.</div></div>

MMED

MiniMed shares rose 7% to $13.14 in pre-market trading after reporting Q4 revenue of $837 million, beating expectations. Growth was driven by a 22% increase in international sales. Additionally, MiniMed expanded its partnership with Abbott Laboratories to commercialize glucose-ketone sensors for its smart dosing systems.

MiniMed Shares Rise on 4Q Sales, Abbott Partnership Expansion